课题基金 / 基金详情

Screening and validation of target molecules involved in mechanism of multi-modality therapy

Screening and validation of target molecules involved in mechanism of multi-modality therapy
多模式治疗机制中靶分子的筛选与验证
批准号:
18590838
负责人:
TAKIGUCHI Yuichi
金额:
$2.43万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

TAKIGUCHI Yuichi的其他基金

相似基金

相关文献

中文摘要
翻译
背景资料:大量证据表明,一些细胞毒性药物在影响细胞信号转导途径方面具有复杂的活性。材料与方法:将人鳞状细胞癌细胞系RERF-LC-AI暴露于低剂量顺铂5天后进行cDNA微阵列分析。通过小干扰RNA抑制上调的基因表达以研究细胞的表型改变。结果:在筛选的30,000个基因中,42个基因在顺铂治疗中表达增加或减少超过2倍。它们包括与细胞凋亡、细胞周期调控和DNA代谢/修复相关的基因。抑制最显着改变的5个基因的小干扰RNA导致部分减少细胞凋亡,而不改变顺铂的细胞毒性。结论:除了对细胞的直接细胞毒性作用外,顺铂可能具有涉及耐药性的间接作用,以及与其他药物的协同作用。
英文摘要
Background: Substantial evidence has disclosed that some cytotoxic agents have complex activities in influencing signal transduction pathways in cells. Materials and Methods: cDNA microarray analysis was performed after exposing a human squamous cell carcinoma cell line, RERF-LC-AI, to low-dose cisplatin for 5 days. Up-regulated gene expressions were suppressed by small interfering RNA to investigate phenotypic alteration of the cells. Results: Among 30,000 genes screened, 42 genes showed increases or decreases in expression of more than 2-fold in cisplatin treatment. They included genes with functions involved in apoptosis, cell cycle regulation and DNA metabolism/repair. Suppression of the most significantly altered 5 genes by small interfering RNA resulted in partly reduced apoptosis without altering cytotoxicity of cisplatin. Conclusion: Besides direct cytotoxic effects on cells, cisplatin may have indirect effects involving drug resistance, and synergistic effects with other agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ヒト肺癌細胞株を用いたシスプラチンによる遺伝子発現変化とその細胞毒性効果の検討
使用人肺癌细胞系检查顺铂引起的基因表达变化及其细胞毒性作用
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [弥富真理, 滝口裕一, 他]
通讯作者: 他
Phase II study of weekly irinotecan and cisplatin for refractory or recurtent non-small cell lung cancer
每周一次伊立替康和顺铂治疗难治性或复发性非小细胞肺癌的 II 期研究
DOI: --
发表时间: 2007
期刊: Lung Cancer 58
影响因子: --
作者: [Takiguchi. Y, et. al.]
通讯作者: et. al.
DOI: 10.1002/cncr.21905
发表时间: 2006-06-01
期刊: CANCER
影响因子: 6.2
作者: [Arai, Makoto, Yokosuka, Osamu, Ochiai, Takenori]
通讯作者: Ochiai, Takenori
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer
氨柔比星治疗难治性或复发性小细胞肺癌的 II 期试验
DOI: --
发表时间: 2006
期刊: Journal of Clinical Oncology 24
影响因子: --
作者: [Onoda, S., et al.]
通讯作者: et al.
共 11 条
    A novel therapy for lung cancer targeting cancer stem cells.
    • 批准号:
      23591136
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2011
    • 负责人:
      TAKIGUCHI Yuichi
    • 依托单位:
    Increase in chemo-and radiotherapy and cancer gene therapy by means of suppression of DNA repair genes
    • 批准号:
      14570540
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.5万
    • 财政年份:
      2002
    • 负责人:
      TAKIGUCHI Yuichi
    • 依托单位:
    Positive interaction between tumor cells and tumor stromal cells for tumor growth.
    • 批准号:
      11670567
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      1999
    • 负责人:
      TAKIGUCHI Yuichi
    • 依托单位:
    海外基金